Relay Therapeutics (RLAY) Interest & Investment Income (2019 - 2026)
Relay Therapeutics (RLAY) reported Interest & Investment Income of $5.4 million for Q1 2026, down 31.5% year-over-year from $7.8 million in Q1 2025, and down 6.27% quarter-over-quarter from $5.7 million in Q4 2025.
Relay Therapeutics (RLAY) Interest & Investment Income (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 8 years of Interest & Investment Income data on file, last reported at $5.4 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $5.4 million, down 31.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.6 million (down 26.88% YoY), and the FY2025 annual result was $27.0 million, down 22.19% from the prior year.
- Interest & Investment Income slipped to $5.4 million in Q1 2026 per RLAY's latest filing, from $5.7 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $9.0 million in Q4 2024 and troughed at $696000.0 in Q1 2022.
- A 5-year average of $6.3 million and a median of $7.1 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 1911.99% in 2022, then sank 36.37% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $5.4 million in 2022, then jumped by 61.95% to $8.7 million in 2023, then increased by 3.15% to $9.0 million in 2024, then slumped by 36.37% to $5.7 million in 2025, then fell by 6.27% to $5.4 million in 2026.
- Business Quant data shows RLAY's Interest & Investment Income at $5.4 million in Q1 2026, $5.7 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | 5.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.35 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Sep 30, 2025 | 6.41 Mn |
| Jun 30, 2025 | 7.11 Mn |
| Mar 31, 2025 | 7.81 Mn |
| Dec 31, 2024 | 8.97 Mn |
| Sep 30, 2024 | 8.27 Mn |
| Jun 30, 2024 | 8.55 Mn |
| Mar 31, 2024 | 8.95 Mn |
| Dec 31, 2023 | 8.70 Mn |
| Sep 30, 2023 | 7.85 Mn |
| Jun 30, 2023 | 7.56 Mn |
| Mar 31, 2023 | 6.94 Mn |
| Dec 31, 2022 | 5.37 Mn |
| Sep 30, 2022 | 1.71 Mn |
| Jun 30, 2022 | 1.01 Mn |
| Mar 31, 2022 | 696,000.00 |
| Dec 31, 2021 | 267,000.00 |
| Sep 30, 2021 | 157,000.00 |
| Jun 30, 2021 | 180,000.00 |